The chief medical officer of AnaptysBio, Paul Lizzul, sold 3,650 shares for $163,191.50 on Thursday. This represented 8.0% of his direct common stock holdings, reducing it from 45,738 to 42,088 shares. The transaction was entirely direct and involved an option exercise with immediate sale of a portion of underlying shares.

The transaction value was based on a weighted average purchase price of $44.71, with post-transaction direct ownership valued at $1.84 million. The sale of 3,650 shares exceeded the recent administrative median of 2,227.5 shares. There were no indirect holdings involved, all shares were held directly by Paul Lizzul.

AnaptysBio is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for inflammation and immuno-oncology. The company generates revenue through product development, milestone payments, and licensing agreements with major pharmaceutical partners. AnaptysBio collaborates with industry leaders on dermatological and immune-mediated diseases.

AnaptysBio ended the third quarter with $256.7 million in cash, with plans to exit 2025 with approximately $300 million. The board expanded its stock repurchase authorization to $100 million in November, reinforcing confidence in royalty inflows and capital flexibility. Paul Lizzul’s sale was an administrative, sell-to-cover event to cover tax obligations tied to RSU vesting, with no discretionary intent.

Read more at Yahoo Finance: What Investors Should Know About a $163K AnaptysBio Insider Sale